` CHRS (Coherus BioSciences Inc) vs S&P 500 Comparison - Alpha Spread

CHRS
vs
S&P 500

Over the past 12 months, CHRS has underperformed S&P 500, delivering a return of -54% compared to the S&P 500's 9% growth.

Stocks Performance
CHRS vs S&P 500

Loading
CHRS
S&P 500
Add Stock

Performance Gap
CHRS vs S&P 500

Loading
CHRS
S&P 500
Difference
www.alphaspread.com

Performance By Year
CHRS vs S&P 500

Loading
CHRS
S&P 500
Add Stock

Competitors Performance
Coherus BioSciences Inc vs Peers

S&P 500
CHRS
ABBV
AMGN
GILD
VRTX
Add Stock

Coherus BioSciences Inc
Glance View

Market Cap
89.2m USD
Industry
Biotechnology

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

CHRS Intrinsic Value
3.91 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top